agriculture
Commented by Fabian Lorenz on October 31st, 2026 | 05:38 CET
Bayer and MustGrow Are Making Concrete Progress, While CTS Eventim Is Entering an Interesting Phase
Created and published on behalf of MustGrow Biologics Corp.
Is CTS Eventim facing turbulent times? An activist US investor is applying pressure, which is unlikely to please founder and major shareholder, Klaus-Peter Schulenberg. The entrepreneur is known for his independent-minded approach and reluctance to compromise. The situation could have implications for the company's share price. MustGrow could also be approaching a significant turning point. Analysts see considerable upside potential, and the company is benefiting from its partnership with Bayer. The two companies recently even held a joint webcast. Bayer itself has also reported positive news, including an important regulatory approval in China.